Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.08 | N/A | -19.73% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.08 | N/A | -19.73% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced in the quarter and emphasized the importance of their ongoing projects. They did not provide detailed guidance, indicating a cautious approach.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on advancing the pipeline despite the current financial results.
PTC Therapeutics reported a larger-than-expected loss per share, which contributed to a decline in stock price by 4.23%. The absence of revenue figures and guidance suggests uncertainty about the company's near-term performance. Investors may be concerned about the lack of clarity on future earnings potential.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WILLIAMS COS INC
Feb 22, 2021